Any feedback?
No. of entries
Information on EC 2.4.1.102 - beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase
for references in articles please use BRENDA:EC2.4.1.102
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree 2 Transferases
2.4 Glycosyltransferases
2.4.1 Hexosyltransferases
2.4.1.102 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase
IUBMB Comments
The enzyme catalyses the addition of N-acetyl-α-D-glucosamine to the core 1 structure of O-glycans forming core 2.
The enzyme appears in viruses and cellular organisms
- 2.4.1.102
- o-glycans
- glycosyltransferases
-
sialylated
-
p-selectin
-
o-linked
- selectins
- ligand-1
-
core-2
- psgl-1
- fuct-vii
- st3gals
- medicine
- poly-n-acetyllactosamine
-
sialyl-lewis
-
udp-glcnac:gal
- diagnostics
-
1-3galnac-r
-
polylactosamine
-
alpha2,3-sialyltransferase
- molecular biology
- synthesis
Reaction Schemes
show+
=
+
+
O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein]
=
+
O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
Synonyms
c2gnt, gcnt3, gcnt1, c2gnt-m, c2gnt1, core 2 glcnac-t, c2glcnact-i, c2gnt-1, c2gnt-l, core 2 beta-1,6-n-acetylglucosaminyltransferase, more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-mucin beta-(1-6)-
-
-
-
-
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-mucin beta-(1-6)-, A
-
-
-
-
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3
-
beta-1,6-N-acetylglucosaminyltransferase
beta6-N-acetylglucosaminyltransferase
-
-
-
-
C2GlcNAcT-I
C2GnT
C2GnT-I
c2GnT-M
C2GnT2
core 2 acetylglucosaminyltransferase
-
-
-
-
core 2 beta-1,6 N-acetylglucosaminyltransferase
core 2 beta-1,6-N-acetylglucosaminyltransferase
core 2 beta1,6-N-acetylglucosaminyltransferase
core 2 beta1,6-N-acetylglucosaminyltransferase I
core 2 GlcNAc-T
core 2 N-acetylglucosaminyltransferase
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
core 6-beta-GlcNAc-transferase A
-
-
-
-
GCNT1
gcnt3
O-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I
-
-
-
-
uridine diphosphoacetylglucosamine-mucin beta-(1-6)-acetylglucosaminyltransferase
-
-
-
-
uridine diphosphoacetylglucosamine-mucin beta-(1-6)-acetylglucosaminyltransferase A
-
-
-
-
additional information
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
-
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
-
-
additional information
core 2 beta6-GalNAc-transferase, EC 2.4.1.102, exists in 2 types, type L and type M, the latter shows an additional core 4 beta6-GalNAc transferase activity
additional information
-
core 2 beta6-GalNAc-transferase, EC 2.4.1.102, exists in 2 types, type L and type M, the latter shows an additional core 4 beta6-GalNAc transferase activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
-
-
-
-
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
C2GnT operates through an inverting mechanism following a SN2-like reaction in which the enzyme provides a catalytic base that activates the nucleophile (in C2GnT, this is the C6 hydroxyl group from a GalNAc residue) to displace the uridine 5'-diphosphate (UDP) leaving group from the UDP-GlcNAc donor in a concerted process. It is assumed that C2GnT follows the ordered bi-bi catalytic mechanism with the UDP-GlcNAc bindings first, followed by the disaccharide acceptor binding over the nucleotide sugar. Reaction mechanism, quantum mechanical/molecular modeling, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hexosyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
MetaCyc
mucin core 1 and core 2 O-glycosylation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetyl-alpha-D-glucosamine:O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-glycoprotein 6-beta-N-acetyl-D-glucosaminyltransferase (configuration-inverting)
The enzyme catalyses the addition of N-acetyl-alpha-D-glucosamine to the core 1 structure of O-glycans forming core 2.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
87927-97-7
-
95978-15-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-GlcNAc + (Galbeta1-3GalNAcalpha1-)TAGV
UDP + (Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TAGV
-
Substrates: pH 7.0, 0.2 mM, 1250% activity
Products: -
Products: -
?
UDP-GlcNAc + 4-nitrophenyl 2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-alpha-D-galactopyranoside
UDP + 4-nitrophenyl 2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6)-[beta-D-galactopyranosyl-(1-3)]-2-(acetylamino)-2-deoxy-alpha-D-galactopyranoside
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-G-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-G-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-G-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-G-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 75% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-GT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-GT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-GT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-GT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 150% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-GTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-GTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-GTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-GTT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTGIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTGIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 50% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTGIST-NH2
UDP + Ac-P-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TTTGIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 200% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-P-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 175% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTGIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTGIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 300% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 200% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTGIST-NH2
UDP + Ac-PT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTGIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 95% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-PT-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TTPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 185% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TGIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TGIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 200% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 100% activity
Products: -
Products: -
?
UDP-GlcNAc + Ac-PTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-PTT-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TPIST-NH2
-
Substrates: pH 7.0, 0.2 mM, 10% activity
Products: -
Products: -
?
UDP-GlcNAc + AP-(Galbeta1-3GalNAcalpha1-)TSS
UDP + AP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TSS
-
Substrates: pH 7.0, 0.2 mM, 250% activity
Products: -
Products: -
?
UDP-GlcNAc + T-(Galbeta1-3GalNAcalpha1-)TTVTPTPTG
UDP + T-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTVTPTPTG
-
Substrates: pH 7.0, 0.2 mM, 75% activity
Products: -
Products: -
?
UDP-GlcNAc + TT-(Galbeta1-3GalNAcalpha1-)TVTPTPTG
UDP + TT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TVTPTPTG
-
Substrates: pH 7.0, 0.2 mM, 75% activity
Products: -
Products: -
?
UDP-GlcNAc + TTTV -(Galbeta1-3GalNAcalpha1-)TPTPTG
UDP + TTTV -(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTPTG
-
Substrates: pH 7.0, 0.2 mM, 75% activity
Products: -
Products: -
?
UDP-GlcNAc + TTTVTP-(Galbeta1-3GalNAcalpha1-)TPTG
UDP + TTTVTP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTG
-
Substrates: pH 7.0, 0.2 mM, 50% activity
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-beta-D-galactosaminyl-4-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-4-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein]
UDP + O3-(beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl)-L-seryl/threonyl-[protein]
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + antifreeze glycoprotein polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-blood group A negative PSM
?
-
Substrates: acceptor contains no fucose
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
-
Substrates: synthetic disaccharide
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methylumbelliferyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methylumbelliferyl
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + D-fucosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + D-fucosyl-beta-1,3-(N-acetyl-D-glucosaminyl beta-1,6)-N-acetyl-alpha-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-methyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP-N-acetyl-D-glucosamine + Galbeta(1-3)GalNAcalpha-p-nitrophenol
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta(1-3)GalNAcalpha-p-nitrophenol
UDP + ?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,3GalNAcalpha1-p-nitrophenyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1-3GalNAcalpha-4-nitrophenyl
?
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + p-nitrophenyl 2-acetamido-2-deoxy-3-O-(beta-D-galactopyranosyl)-alpha-D-galactopyranoside
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-alpha1 acid glycoprotein
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-alpha1 acid glycoprotein
?
Substrates: no activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
-
Substrates: ovine asialo-submaxillary mucin
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
Substrates: bovine asialo-submaxillary mucin
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialofetuin
?
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialofetuin
?
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialoglycophorin A
?
Substrates: best substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + asialoglycophorin A
?
-
Substrates: best substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: at high concentration inhibitory
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: at high concentration inhibitory
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: at high concentration inhibitory
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
Substrates: requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: inhibitory under UV-radiation
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: substrate specificity
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: substrate specificity
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
Substrates: substrate specificity
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: large scale preparation
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: highly specific for both substrates
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in regulation of downstream intracellular signal transduction pathways
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in the development of cardiomyopathy
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: increased activity during E- and P-selectin ligand biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: -
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: highly specific for UDP-N-acetyl-D-glucosamine
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: i.e. core class 1, R: polypeptide
Products: i.e. core class 2
Products: i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fetuin
?
Substrates: no activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: low activity
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,3GalNAc-O-p-nitrophenyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + Galbeta1,3GalNAc-O-p-nitrophenyl
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
Substrates: enzyme shows both core 2 beta6-GalNAc-transferase activity, EC 2.4.1.102, and core 4 beta6-GalNAc-transferase activity, EC 2.4.1.148, and is termed a type M core 2 beta6-GalNAc-transferase
Products: i.e. core 4
Products: i.e. core 4
?
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
Substrates: i.e. core 3
Products: i.e. core 4
Products: i.e. core 4
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + phenyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + phenyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine or ovine origin of acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
Substrates: porcine acceptor substrate
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + trachea mucin
?
-
Substrates: acceptor substrate is deglycosylated
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + trachea mucin
?
-
Substrates: porcine or human trachea mucin
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme catalyzes the formation of all mucin beta1,6-N-acetylglucosaminides, including core 2, core 4, and blood group I structures
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrates: lactose, Galbeta1-3GlcNAc, L-Fucalpha1-2Galbeta1-3GalNAc-OH, alpha- and beta-methylglycosides of galactose
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: attachment of UDPGlcNAc to serine or threonine residue
Products: -
Products: -
?
additional information
?
-
Substrates: no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
Products: -
Products: -
?
additional information
?
-
Substrates: no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
Products: -
Products: -
?
additional information
?
-
Substrates: no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
Products: -
Products: -
?
additional information
?
-
-
Substrates: no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
Products: -
Products: -
?
additional information
?
-
-
Substrates: patients with Wiskott-Aldrich-Syndrome show an altered enzyme activity and inversed enzyme stimulation in T cells, enzyme activity in platelets is 3fold higher compared to normal organisms
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
Products: -
Products: -
?
additional information
?
-
-
Substrates: M isoform is upregulated by both all-trans retinoic acid and by IL-4/13. L-isoform is moderately upregulated by IL-4/13 but not by all-trans retinoic acid
Products: -
Products: -
?
additional information
?
-
-
Substrates: the M isoform of C2GnT can form all mucin glycan beta1,6-branched structures, including core 2, core 4, and blood group I antigen. The L-isoform forms only core 2 structures
Products: -
Products: -
?
additional information
?
-
-
Substrates: C2GnT-1 regulates selectin ligand expression. Downregulation of the selectin ligand expression level inhibits tissue infiltration of BCP-leukemia cells
Products: -
Products: -
?
additional information
?
-
-
Substrates: glucose levels, plasma TNF-alpha nd core 2 GlcNAc-T activity are functionally linked with dabetic retinopathy
Products: -
Products: -
?
additional information
?
-
-
Substrates: key enzyme for the biosynthesis of sialyl-Lewis x determinants on selectin ligands
Products: -
Products: -
?
additional information
?
-
-
Substrates: transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
Products: -
Products: -
?
additional information
?
-
Substrates: KRT1 binds the biotinylated CT peptide MVQWKRL of C2GnT-M isozyme
Products: -
Products: -
?
additional information
?
-
-
Substrates: KRT1 binds the biotinylated CT peptide MVQWKRL of C2GnT-M isozyme
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
Products: -
Products: -
?
additional information
?
-
-
Substrates: multiple C2GlcNAcT enzymes can contribute to P-selectin ligand formation and may cooperate with C2GlcNAcT-I in the control of CD8 T cell trafficking
Products: -
Products: -
?
additional information
?
-
-
Substrates: haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
Products: -
Products: -
?
additional information
?
-
Substrates: the isozyme exhibits exclusive core 2 acceptor specificity. C2GnT operates through an inverting mechanism
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
Products: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
Products: -
Products: -
?
additional information
?
-
-
Substrates: attachment of UDPGlcNAc to serine or threonine residue
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
Substrates: -
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in regulation of downstream intracellular signal transduction pathways
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in the development of cardiomyopathy
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: increased activity during E- and P-selectin ligand biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in biosynthesis of O-glycans core class 2
Products: -
Products: -
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
Substrates: involved in mucin oligosaccharide biosynthesis
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme catalyzes the formation of all mucin beta1,6-N-acetylglucosaminides, including core 2, core 4, and blood group I structures
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: patients with Wiskott-Aldrich-Syndrome show an altered enzyme activity and inversed enzyme stimulation in T cells, enzyme activity in platelets is 3fold higher compared to normal organisms
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
Products: -
Products: -
?
additional information
?
-
-
Substrates: M isoform is upregulated by both all-trans retinoic acid and by IL-4/13. L-isoform is moderately upregulated by IL-4/13 but not by all-trans retinoic acid
Products: -
Products: -
?
additional information
?
-
-
Substrates: C2GnT-1 regulates selectin ligand expression. Downregulation of the selectin ligand expression level inhibits tissue infiltration of BCP-leukemia cells
Products: -
Products: -
?
additional information
?
-
-
Substrates: glucose levels, plasma TNF-alpha nd core 2 GlcNAc-T activity are functionally linked with dabetic retinopathy
Products: -
Products: -
?
additional information
?
-
-
Substrates: key enzyme for the biosynthesis of sialyl-Lewis x determinants on selectin ligands
Products: -
Products: -
?
additional information
?
-
-
Substrates: transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
Products: -
Products: -
?
additional information
?
-
-
Substrates: multiple C2GlcNAcT enzymes can contribute to P-selectin ligand formation and may cooperate with C2GlcNAcT-I in the control of CD8 T cell trafficking
Products: -
Products: -
?
additional information
?
-
-
Substrates: haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
Products: -
Products: -
?
additional information
?
-
-
Substrates: overview: structure of O-glycans
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Mg2+
Mn2+
additional information
Mn2+
-
slight stimulation, 5 mM, inhibits at higher concentration
additional information
metal ion-independent enzyme. The enzyme does not contain the metal-ion-binding DXD pattern typical for inverting glycosyltransferases with the GT-A fold
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
12-O-tetradecanoylphorbol-13-acetate
-
about 10fold decreased activity, down-regulation of native enzyme in KM3 leukemia cell line, but not of the recombinant enzyme; i.e. TPA
5,5'-dithiobis-2-nitrobenzoic acid
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 1 mM inhibits 94%
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
and other nitrophenyl-sugar-derivatives; strong inhibition under UV-radiation at 350 nm, specific for substrate binding site, preincubation with beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl partially protects
Hydroxyphenylglyoxal
-
19% inhibition at 0.25 mM, complete inhibition at 5-10 mM
jacalin
core 1 O-glycan-specific lectin from Artocarpus integrifolia, differing sensitivity of different BoHV-4 mutants to jacalin-mediated neutralization, overview
-
NEM
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 0.2 mM inhibits 42%
substrate analogues lacking the 6-hydroxyl of the N-acetylgalactosamine
-
weak
-
Triton X-100
-
activation at 0.1% v/v, inhibition at higher concentrations, pig stomach
tunicamycin
-
inactivation; prevents secretion of recombinant enzyme from Sf9 cells
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
high concentration
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
high concentration
Mn2+
-
slight stimulation at 5 mM, inhibition at higher concentrations
talniflumate
selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview
talniflumate
selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview
UDP
-
competitive inhibition versus donor substrate, wild-type enzyme and mutant enzyme C217S
additional information
Bo17 splicing reduces BoHV-4 glycosylation
-
additional information
-
no effect of dimethyl sulfoxide, retinoic acid, phorbol ester, cholera toxin
-
additional information
-
the mutant enzyme C217S is insensitive to DTNB, iodoacetamide, NEM, HgCl2 and ZnCl2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
sodium butyrate
-
induction after treatment of cells for 24 h, 16fold increase in activity, blocked by actinomycin D and cycloheximide
additional information
-
no effect of dimethyl sulfoxide, retinoic acid, phorbol ester, cholera toxin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.86
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
-
-
-
4.2
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-methyl
-
-
-
0.92
beta-D-galactosyl-1,3-N-acetyl-beta-D-galactosaminyl-4-nitrophenyl
-
-
-
0.6
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
AML cell line
3.3
3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
AML cell line
6.7
4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
AML cell line
0.52
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
-
-
0.92
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
-
-
0.77
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
-
-
0.8
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
-
AML cell line
0.36
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
undifferentiated CaCo-2, colonic adenocarcinoma, cells
0.43
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
CaCo-2, colonic adenocarcinoma, cells differentiated to enterocytes
2.8
UDP-N-acetyl-D-glucosamine
mutant enzyme C217S, in 50 mM Tris (pH 7.5), at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.95
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
AML cells
2.5
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
CML cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
overview: enzyme activities with several substrates
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
30
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
human Panc 1/MUC1f cells stably transfected with pcDNA3.1 containing bC2GnT-1 cDNA controlled by CMV promoter. Butyrate treatment enhances C2GnT activity in Panc 1/MUC1f-bC2GnT-1 cells in a time and butyrate concentration dependent fashion
-
-
brenda
BoHV-4, strains LVR 140, MOVAR 33/63, DN599, 66-P-347, 108, 130, and Buf representative of the BoHV-4 species isolated throughout the world and from different animal species
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
GCNT3 is elevated in skin and mesothelioma cells and in some lung and breast cancer cells
brenda
differential expression of GCNT3 gene among tumour samples from stage II colon cancer patients by quantitative reverse-transcription PCR, overview
brenda
GCNT3 gene expression is downregulated in colorectal cancer (CRC) samples in comparison to non-pathological colon tissue
brenda
-
maturation of dendritic cells leads to a rapid change in the expression of glycosyltransferases involved in O-linked glycosylation. A down-regulation of C2GnT1 mRNA and enzymatic activity is observed with a concurrent up-regulation of ST3Gal I and ST6GalNAc II mRNA resulting in a loss of the core 2 structures required for sLex expression as a P-selectin ligand
brenda
-
expression of C2GnT1 in 84 cases of endometrioid-type endometrial carcinoma, 15 cases of endometrial hyperplasia, and 30 normal endometria, immunohistochemic analysis, overview. C2GnT1 is strongly expressed at the invasive tumour front in several cases
brenda
GCNT3 expression analysis in a cohort of 56 EOC patients, followed by a meta-analysis of more than one thousand patients, overview
brenda
GCNT3 expression in Epstein-Barr virus (EBV)-associated gastric cancer cells and tissues is lower than in EBV-negative gastric cancer cells (EBVnGC) and tissues, and high expression is significantly associated with advanced tumor-lymph node metastasis. GCNT3 is closely related to the ERK signaling pathway and epithelial mesenchymal transition (EMT), regulating cell proliferation, migration, and invasion
brenda
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
brenda
GCNT3 is overexpressed in highly metastatic melanomas
brenda
GCNT3 is highly expressed in both NSCLC tissues and cell lines
brenda
-
colonic large ulcerating grade IV tumour cell line, low activity
brenda
additional information
-
acute myeloid leukemia blast cell line
brenda
-
18fold increased level compared to normal granulocytes
brenda
-
core 2 N-acetylglucosaminyltransferase is downregulated in galectin-1-resistant PSA-LNCaP cells compared with galectin-1-sensitive PSA+ LNCaP cells
brenda
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
brenda
genetically engineered Kras-driven mouse pancreatic tumors
brenda
-
genetically engineered Kras-driven mouse pancreatic tumors
-
brenda
-
core2GnT and core 2-branched O-glycans synthesized play a critical role in prostate cancer progression. Core2GnT in prostate carcinoma cells facilitates adhesion to type IV collagen and laminin, and this increased adhesion may be a cause for aggressive tumor formation by prostate cancer cells expressing core2GnT
brenda
-
GCNT1 immunohistochemic analysis, overview. The anti-GCNT1 monoclonal antibody shows high specificity against human GCNT1
brenda
-
wild-type and transgenic CD4+ T cell lines, induction by cytokines IL-4, and IL-12/STAT4
brenda
additional information
expression during virus replication cycle, MDBK cells
brenda
additional information
-
expression during virus replication cycle, MDBK cells
brenda
additional information
infection of MDBK cells with strain BoHV-4 V.test
brenda
additional information
-
production of Anti-Bo17 422-441 polyclonal monospecific antibodies from BoHV-4 V.test strain Bo17 protein and immunohistochemic analysis
brenda
additional information
-
infection of MDBK cells with strain BoHV-4 V.test
-
brenda
additional information
human pancreatic cancer tissue array consisting of 90 cases of tumor and matched normal adjacent tissue with survival data, overview
brenda
additional information
-
human pancreatic cancer tissue array consisting of 90 cases of tumor and matched normal adjacent tissue with survival data, overview
brenda
additional information
the isozyme is distributed in mucin-secreting tissues along the gastrointestinal tract
brenda
additional information
-
the isozyme is distributed in mucin-secreting tissues along the gastrointestinal tract
brenda
additional information
-
topologically, C2GnT1 is strongly expressed at sites of deep myometrial invasion
brenda
additional information
GCNT3 is highly expressed in both NSCLC tissues and cell lines, and higher expression is significantly associated with advanced tumor lymph node metastasis (TNM) stage, positive lymph node metastasis, and poor overall survival. GCNT3 expression is associated with lymph node metastasis and age. But the expression level of GCNT3 is not correlated with gender, tumor location, differentiation grade, etc.. Expression of GCNT3 is lower in EBVaGC cells and tissues than that in EBVnGC cells and tissues
brenda
additional information
-
GCNT3 is highly expressed in both NSCLC tissues and cell lines, and higher expression is significantly associated with advanced tumor lymph node metastasis (TNM) stage, positive lymph node metastasis, and poor overall survival. GCNT3 expression is associated with lymph node metastasis and age. But the expression level of GCNT3 is not correlated with gender, tumor location, differentiation grade, etc.. Expression of GCNT3 is lower in EBVaGC cells and tissues than that in EBVnGC cells and tissues
brenda
additional information
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation. The non-invasive HT-29 cell line, that is isolated from a primary tumor, shows GCNT3 expression (mRNA and protein). By contrast, cells belonging to metastatic and invasive SW family, e.g. SW620 and SW5FU, do not exhibit measurable GCNT3 expression
brenda
additional information
-
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation. The non-invasive HT-29 cell line, that is isolated from a primary tumor, shows GCNT3 expression (mRNA and protein). By contrast, cells belonging to metastatic and invasive SW family, e.g. SW620 and SW5FU, do not exhibit measurable GCNT3 expression
brenda
additional information
STAT4 controls Gcnt1 expression in Th1 cells, several several conserved and non-conserved predicted STAT4 binding sites are determined. Functional importance of STAT4 for P-lig induction and specifically on the enhancer as a transactivating factor. Prolonged T-bet binding to the Gcnt1 enhancer
brenda
additional information
transcriptome analysis in pacreatic carcinomas and healthy tissues
brenda
additional information
-
transcriptome analysis in pacreatic carcinomas and healthy tissues
brenda
additional information
-
transcriptome analysis in pacreatic carcinomas and healthy tissues
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
secretion into medium of the recombinant enzyme from Sf9 cells
-
brenda
secretion into medium of the recombinant enzyme from Sf9 cells
-
brenda
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain
brenda
additional information
isozyme C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail. C2GnT-M forms a complex with Giantin before KRT1, demonstrating CT-mediated sequential events of Golgi targeting and retention of C2GnT-M
-
brenda
additional information
-
isozyme C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail. C2GnT-M forms a complex with Giantin before KRT1, demonstrating CT-mediated sequential events of Golgi targeting and retention of C2GnT-M
-
brenda
Highest Expressing Human Cell Lines
Cell Line LinksPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
malfunction
metabolism
physiological function
additional information
evolution
in contrast to cellular homologues, this virus has evolved to alternatively express two proteins from gene Bo17
evolution
-
the viral 17 gene encodes a functional homologue of the cellular Corebeta1,6GnT typeM(C2GnT-M), which was acquired from a recent ancestor of the African buffalo. Bo17 splicing is conserved among BoHV-4 strains but not in its cellular counterparts
evolution
-
in contrast to cellular homologues, this virus has evolved to alternatively express two proteins from gene Bo17
-
malfunction
C2GnT2 deficiency, impair of mucosal barrier, increase of susceptibility to colitis, reduced immunoglobulin abundance, loss of all core 4 O-glycan biosynthetic activity
malfunction
-
higher presence of the enzyme in higher stages of testicular germ cell tumors, promotes aggressive behavior of cancer cells
malfunction
-
in C2GlcNAc-TI deficient mice, decreased monocyte interactions, inhibition of monocyte recruitment, formation of small, macrophage-poor and collagen-rich atherosclerotic lesions
malfunction
a Bo17 knockout strain does not display any growth deficit in vitro. But sole expression of either of the two Bo17-encoded proteins could influence BoHV-4 growth
malfunction
aberrant GCNT3 expression is associated with increased mucin production, aggressive tumorigenesis, and reduced patient survival, and CRISPR-mediated knockout of GCNT3 in pancreatic cancer cells reduces proliferation and spheroid formation. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
malfunction
GCNT1-overexpressing cells produce a significantly larger amount of growth factors when cocultured with prostate stromal cells compared with GCNT1-knocked down cells and form larger tumors
malfunction
in mouse pancreatic cancer tumors, GCNT3 103fold upregulation is correlated with increased expression of mucins by 5-87fold. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. CRISPR GCNT3-KO leads to reduced cell viability and spheroid formation
malfunction
loss of C2GnT-M leads to development of colitis and colon cancer. Knockdown of KRT1 by siRNA does not affect Golgi morphology but leaves C2GnT-M outside of the Golgi, resulting in the formation of sialyl-T antigen
malfunction
Gcnt1-/-Th1 cells lacking C2-GlcNAcT-I expression show impaired P-lig expression similar to Fut4+7-/-Th1 cells. In contrast to impaired P-lig expression,Gcnt1-/-and Fut4 +7-/- maintain their inflammatory competence as assessed by IFNgamma expression. Functional relevance of Gcnt1 deficiency in CD4+T cells in vivo. In line with a lack of Gcnt1 transcription, naive T cells exhibit a closed histone configuration with lowH3K4me2 and prominent H3K27me3 marks. The active H3K4me2 mark in this region increases in a time-dependent manner during Th1 differentiation
malfunction
GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. The enzyme's overexpression in epithelial ovarian cancer (EOC) patients is associated with better clinical outcome and response to initial therapy
malfunction
miR-BART1-5p directly targets GCNT3. In addition, miR-BART1-5p mimics transfection is observed to reduce cell proliferation and migration, while miR-BART1-5p inhibitor increases cell proliferation and migration following transfection. In conclusion, both miR-BART1-5p and knockdown of GCNT3 inhibit cell proliferation and migration
malfunction
silencing and functional inhibition of GCNT3 greatly suppresses migration and invasion of melanoma cells, resulting in the loss of S100A8/A9 responsiveness. siRNA-mediated GCNT3 suppression and talniflumate-mediated GCNT3 suppression significantly attenuate the basal ability of in vitro migration of WM-266-4 cells
malfunction
-
the Bo17 knockout strain does not display any growth deficit in vitro
malfunction
-
in mouse pancreatic cancer tumors, GCNT3 103fold upregulation is correlated with increased expression of mucins by 5-87fold. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. CRISPR GCNT3-KO leads to reduced cell viability and spheroid formation
-
malfunction
-
a Bo17 knockout strain does not display any growth deficit in vitro. But sole expression of either of the two Bo17-encoded proteins could influence BoHV-4 growth
-
metabolism
O-glycan biosynthesis pathways and proposed O-glycan structures of selected glycosyltransferases, overview. Core 1 dominates the O-glycan repertoire. Core 1 can be further elongated by extended C1 beta3GnT3 enzyme, EC 2.4.1.146, to form extended core 1 structure, or be modified by C2 beta6GnT1 enzyme to form core 2 O-glycans. Three core 2 enzymes, C2 beta6GnT1, 2, and 3, are responsible for biosynthesis of core 2 O-glycans. C2 beta6GnT1 and 3 are almost exclusively responsible for biosynthesis of the core 2 branch, while C2 beta6GnT2 shows a significant core 4 and I-branching activity. Regulation of O-glycan biosynthesis, overview
metabolism
the enzyme is involved in the biosynthetic pathways for core2 O-glycans, overview. The core1 structure is converted to branched core2 structure (Core2) by GCNT1, GCNT3, and GCNT4
metabolism
as all fucosyltransferases 8 (FUT8), GnT-III, GnT-IV, and GnT-V use GlcNAc terminated bi-antennary glycan as acceptor substrate, the interplay among these enzymes determines the forms of glycans, e.g. the bisecting modification by GnT-III makes the glycan no longer a substrate for FUT8 and GnT-V
metabolism
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. The vascular epithelial growth factor A (VEGFA) arises as an attractive partner of GCNT3 functions in cell invasion and resistance
physiological function
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing. The enzyme is a homologue of the cellular core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type (C2GnT-M), which is a key player for the synthesis of complex O-glycans
physiological function
-
C2GnT1 synthesizes the core 2 branching structure by catalysing the transfer of GlcNAc from UDP-GlcNAc with a beta1,6-linkage to GalNAc of the core 1 chain. On this core 2 branch, several tumour-associated carbohydrate structures, such as sLex and sLea, are synthesized. The enzyme may be associated with the biological aggressiveness of tumour cells, relationship between the expression of C2GnT1 and clinicopathological parameters of patients with endometrial carcinoma, overview
physiological function
core 2 beta-1, 6-N-acetylglucosaminyltransferase-1 (GCNT1) is a key enzyme that forms core 2 branched O-glycans. GCNT1 expression is correlated with D'Amico's recurrence risk classification. GCNT1-negative tumors are associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. GCNT1 expression status is an independent risk factor for PSA recurrence after radical prostatectomy
physiological function
-
enzyme GCNT1 expression in prostate cancer specimens from radical prostatectomy correlates with prostate cancer aggressiveness
physiological function
mucin-type isozyme core 2 N-acetylglucosaminyltransferase 2/M synthesizes all three beta6GlcNAc branch structures found in secreted mucins
physiological function
the isozyme shows tumour suppressor properties, together with a role of mucin production in chemotherapy sensitivity in pancreatic cancer
physiological function
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis
physiological function
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis. Correlation between GCNT3 expression and patient survival in human pancreatic cancer
physiological function
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3) is a glycosyltransferase that transfers GlcNAc to N-acetylgalactosamine (GalNAc) of the core 1 acceptor structure to form the core 2 branch in the beta-1,6 linkage. In addition to the formation of the core 2 structure, GCNT3 also functions to form the core 4 structure. GCNT3 increases MCAM stability, which enhances S100A8/A9-mediated cancer motility. Among the novel S100A8/A9 receptors, GCNT3 favorably glycosylates the MCAM receptor, extending its half-life and leading to further elevation of S100A8/A9-mediated cellular motility in melanoma cells. GCNT3 plays a pivotal role in the maintenance of MCAM protein at a high level, resulting in the acquisition of strong responsiveness to S100A8/A9 that is linked to increased cellular migration and invasion. GCNT3 expression is positively correlated to MCAM expression in patients with high-grade melanomas. GCNT3 is an upstream regulator of MCAM protein. GCNT3 plays a key role in S100A8/A9-mediated cancer motility. GCNT3 controls MCAM stability by its catalytic activity-mediated glycosyl modification that correlates with a greater ability for cancer cell motility and invasion in response to extracellular S100A8/A9
physiological function
core 2 beta1,6-N-acetylglucosaminyltransferase-I (C2GlcNAcT-I) is crucial for inflammatory homing of Th1 cells to the skin in vivo, analysis of molecular regulation of the enzyme encoded by gene Gcnt1 in CD4+T helper cells, overview. C2-GlcNAcT-I, encoded by Gcnt1, is essential for generation of P-lig and recruitment of Th1 cells into a skin-DTH reaction. Gcnt1 transcription and subsequent P-lig induction in Th1 cells is governed by binding of STAT4 and T-bet to a distal enhancer and further regulated by epigenetic marks such as H3K27me3. T-cells cultured in vitro under Th1 conditions, i.e. supplemented with IL-12, IFN gamma, and anti-IL-4, but not under Th2 (IL-4, anti-IL-12, anti-IFN gamma) or Th0 (anti-12, anti-IFNgamma and anti-IL-4) conditions, express P-lig, which corresponds to differential Gcnt1 but not Fut7 mRNA expression. STAT4 controls Gcnt1 expression in Th1 cells, several several conserved and non-conserved predicted STAT4 binding sites are determined. Functional importance of STAT4 for P-lig induction and specifically on the enhancer as a transactivating factor. Prolonged T-bet binding to the Gcnt1 enhancer
physiological function
O-glycan synthase glucosamine (N-acetyl) transferase 3 (GCNT3) is a mucin-type responsible for catalyzing core 2 and core 4 O-glycans and forming O-linked glycosylation in protein biosynthesis. Abnormal expression of GCNT3 promotes the progression of several human cancers. GCNT3 expression in Epstein-Barr virus (EBV)-associated gastric cancer cells and tissues is lower than in EBV-negative gastric cancer cells and tissues, and high expression is significantly associated with advanced tumor-lymph node metastasis. EBV may regulate GCNT3 by affecting the NF-kappaB signaling pathway. Patients with EBV-associated gastric cancer (EBVaGC) have a good survival rate. EBV potentially regulates GCNT3 by affecting the NF-kappaB signaling pathway
physiological function
-
the Bo17 gene is nonessential for virus replication, despite its contributing to posttranslational modification of virion proteins. Bo17 undergoes an alternative splicing that generates two different products of expression. In contrast to the full-length form of the protein, the shortened spliced form is devoid of enzymatic activity and confers to BoHV-4 the potential to fine-tune the core 2 branching activity of the infected cell, mechanisms to regulate the activity of glycosyltransferases from the Golgi apparatus, overview. O-Glycomic profile analysis of wild-type and mutant strains. Sole expression of either of the two Bo17-encoded proteins can influence BoHV-4 growth. Bo17 expression and splicing may affect the structure of O-glycans on BoHV-4 virions and in particular on glycoprotein gp180
physiological function
the mucin-type core 2 1,6-N-acetylglucosaminyltransferase enzyme (C2GnT-M), encoded by the GCNT3 gene, is a glycosyltransferase enzyme whose expression is altered in cancer processes. GCNT3 catalyzes the formation of core 2 O-glycan, core 4 O-glycan and I branches and its pattern of expression is mainly associated with colorectal cancer (CRC) prognosis. GCNT3 transfection in certain CRC cells reduces cell proliferation, adhesion, invasion, and induced cell death, and also inhibits tumor growth in vivo. Role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance, overview. Integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. GCNT3 overexpression contributes to reduce 5-fluorouracil resistance in metastatic CRC cells. GCNT3 also diminishes cell invasion and VEGFA expression in EOC cells. GCNT3 is a cancer prognostic factor. GCNT3 diminishes cell proliferation, invasion and alters metabolic properties of CRC cells. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome
physiological function
-
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis
-
physiological function
-
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing. The enzyme is a homologue of the cellular core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type (C2GnT-M), which is a key player for the synthesis of complex O-glycans
-
additional information
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain. Keratin 1 plays a critical role in the regulation of O-glycosylation pathways
additional information
-
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain. Keratin 1 plays a critical role in the regulation of O-glycosylation pathways
additional information
quantum mechanical/molecular modeling using enzyme crystal structures, PDB IDs 2GAK and 2GAM, as templates. C2GnT may occur in an open conformation, and a closed conformation. The location of the C2GnT-conserved Glu320 residue structurally corresponds to the catalytic base found in other glycosyltransferases with the GT-A fold. The enzyme-substrate system (C2GnT-UDP-GlcNAc-Galb1-3GalNAc ternary complex) consists of 379 amino acids, eight water molecules, donor, and acceptor, active site model
additional information
the two isoforms of Bo17 are expressed in BoHV-4 infected cells, but enzymatic assays revealed that the spliced form is not active
additional information
no effect of core fucosylation of substrate on the glycosyltransferase activity of GnT-III, overview
additional information
-
the splicing of the Bo17 gene gives the potential to BoHV-4 to fine-tune the global level of core 2 branching activity in the infected cell. Analysis of the structures of O-glycans isolated from cells mock infected or infected with the Bo17 Del, Bo17 MuDir, Bo17 MuDir Rev, Bo17 Spliced, and Bo17 Spliced Rev strains of BoHV-4
additional information
-
the two isoforms of Bo17 are expressed in BoHV-4 infected cells, but enzymatic assays revealed that the spliced form is not active
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). GCNT3_RAT
437
1
50642
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_SHEEP
440
1
50860
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_SYNCA
440
1
51079
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_XENLA
443
0
51202
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT4_DANRE
428
1
49928
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT4_HUMAN
453
1
53052
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT4_MOUSE
455
1
52832
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT1_BOVIN
427
1
49734
Swiss-Prot
Secretory Pathway (Reliability: 4)
GCNT1_HUMAN
428
1
49799
Swiss-Prot
Mitochondrion (Reliability: 5)
GCNT1_MOUSE
428
1
49839
Swiss-Prot
Mitochondrion (Reliability: 5)
GCNT3_BHV4
439
1
50741
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BHV4D
Bovine herpesvirus 4 (strain DN-599)
440
1
50764
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT3_BHV4L
Bovine herpesvirus 4 (strain LVR140)
440
1
50720
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BHV4V
Bovine herpesvirus 4 (strain V. test)
440
1
50702
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BOSMU
440
1
50909
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BOVIN
440
1
50953
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BUBBU
440
1
51008
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_HUMAN
438
1
50864
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_MOUSE
437
1
50698
Swiss-Prot
Secretory Pathway (Reliability: 1)
A0A2H5CAB7_ELHV1
218
0
25290
TrEMBL
other Location (Reliability: 2)
A0A6J8E0X8_MYTCO
377
1
44292
TrEMBL
other Location (Reliability: 4)
A0A8B6FP45_MYTGA
409
1
48273
TrEMBL
Secretory Pathway (Reliability: 2)
A0A812DWE5_SEPPH
225
0
25643
TrEMBL
other Location (Reliability: 1)
A0A2H5CAC5_ELHV1
218
0
25218
TrEMBL
other Location (Reliability: 2)
M4JWY2_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A6J8E209_MYTCO
418
0
49205
TrEMBL
Mitochondrion (Reliability: 5)
A0A6J8BCG2_MYTCO
271
0
31377
TrEMBL
other Location (Reliability: 2)
F9XAV2_ZYMTI
Zymoseptoria tritici (strain CBS 115943 / IPO323)
490
1
56649
TrEMBL
Secretory Pathway (Reliability: 1)
A0A6J8D8U9_MYTCO
156
0
18109
TrEMBL
other Location (Reliability: 4)
A0A6J8CZB6_MYTCO
435
1
50817
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6DBS3_MYTGA
509
1
59996
TrEMBL
Secretory Pathway (Reliability: 4)
A0A866VUR1_ELHV1
422
0
49197
TrEMBL
Secretory Pathway (Reliability: 5)
A0A2H5CAA2_ELHV1
416
0
48464
TrEMBL
other Location (Reliability: 2)
A0A866VRV4_9BETA
528
1
58552
TrEMBL
Mitochondrion (Reliability: 3)
Q801N9_XENLA
428
1
49809
TrEMBL
Secretory Pathway (Reliability: 3)
A0A812EU53_SEPPH
323
0
37866
TrEMBL
other Location (Reliability: 2)
A0A6J7ZW16_MYTCO
453
0
52917
TrEMBL
other Location (Reliability: 2)
A0A6J8DMF7_MYTCO
509
1
59894
TrEMBL
Secretory Pathway (Reliability: 5)
A0A6J8D6P1_MYTCO
353
0
41198
TrEMBL
other Location (Reliability: 3)
A0A6J8CWC1_MYTCO
389
0
45556
TrEMBL
Secretory Pathway (Reliability: 5)
A0A075CZK4_9BETA
443
1
51385
TrEMBL
Secretory Pathway (Reliability: 1)
A0A2H5CAR1_ELHV1
409
0
47629
TrEMBL
other Location (Reliability: 2)
A0A8B6EH56_MYTGA
456
0
53038
TrEMBL
other Location (Reliability: 5)
A0A8F9XNQ7_ELHV1
488
2
57022
TrEMBL
Secretory Pathway (Reliability: 3)
A0A6J8CTV4_MYTCO
391
0
46121
TrEMBL
Secretory Pathway (Reliability: 5)
A0A6J8BQ54_MYTCO
438
0
51105
TrEMBL
other Location (Reliability: 3)
A0A0S1TKJ6_9BETA
538
1
59937
TrEMBL
other Location (Reliability: 4)
A0A8B6C910_MYTGA
420
0
50081
TrEMBL
Mitochondrion (Reliability: 4)
A0A2L2FP41_ELHV1
441
1
51421
TrEMBL
Secretory Pathway (Reliability: 1)
M1RFT8_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6BYD4_MYTGA
401
0
47098
TrEMBL
other Location (Reliability: 1)
A0A812DRH1_SEPPH
531
3
62014
TrEMBL
Secretory Pathway (Reliability: 5)
M4JZ77_ELHV1
441
1
51346
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6FRL1_MYTGA
390
0
46131
TrEMBL
other Location (Reliability: 3)
A0A8B6FRL1_MYTGA
390
0
46131
TrEMBL
other Location (Reliability: 3)
A0A2H5CAA3_ELHV1
416
0
48476
TrEMBL
other Location (Reliability: 2)
A0A866VU70_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A866VTI8_ELHV1
441
1
51390
TrEMBL
Secretory Pathway (Reliability: 1)
A0A812E0M3_SEPPH
267
0
30626
TrEMBL
other Location (Reliability: 1)
A0A2H5CAA0_ELHV1
416
0
48464
TrEMBL
other Location (Reliability: 2)
A0A8B6ENQ5_MYTGA
377
0
43988
TrEMBL
other Location (Reliability: 1)
A0A8B6BV66_MYTGA
405
0
48326
TrEMBL
other Location (Reliability: 2)
A0A866VT55_ELHV1
441
1
51489
TrEMBL
Secretory Pathway (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
dimer
the monomer units of the observed dimer C2GnT possesses the GT-A fold and are connected by a disulfide bond between the Cys235 residues, quantum mechanical/molecular modeling using enzyme crystal structures, PDB IDs 2GAK and 2GAM, as templates. The structure of C2GnT contains two regions; the first (38-121) is composed of alpha-helices. The second region, which corresponds to the catalytic domain (122-428), is an alpha/beta/alpha structure consisting of a central six-stranded mixed beta-sheet. Four disulfide bonds are found in each monomer (Cys151-Cys199, Cys372-Cys381, Cys59-Cys413, and Cys100-Cys172), the remaining Cys217 is unpaired and located in the donor binding site. C2GnT may occur in an open conformation, and a closed conformation. The location of the C2GnT-conserved Glu320 residue structurally corresponds to the catalytic base found in other glycosyltransferases with the GT-A fold
monomer
additional information
-
in absence of dithiothreitol, one of the two free Cys residues (Cys217 and Cys235) is found to be engaged in an intermolecular bridge causing dimerization of the protein
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
glycoprotein
-
for C2GnT-I, the N-glycan chain linked to Asn-95 significantly contributes to the synthesis of functional P-selectin glycoprotein ligand-1 and is required to localize the enzyme to the cis/medial-Golgi compartment
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
C217S mutant in complex with UDP, hanging drop vapor diffusion method, using 24% (w/v) polyethylene glycol 4000, 0.1 M glycine (pH 9.0) and 0.6 M LiCl
hanging drop vapor diffusion method, X-ray crystal structures of murine C2GnT-L in the absence and presence of the acceptor substrate Galbeta1,3GalNAc at 2.0 and 2.7 A resolution, respectively
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
C217S
-
mutant enzyme with 41% of wild-type activity. Similar Km and Vmax values for Galbeta(1-3)GalNAcalpha-p-nitrophenol, Km-value for UDP-N-acetyl-D-glucosamine is 2.9fold higher than wild-type value. In contrast to wild-type enzyme, the mutant enzyme is not inhibited by sulfhydryl reagents and is not stimulated by reducing agents
T60A
T60A/T97A
T97A
C217S
S158C
-
mutation reduces C2GnT activity but does not affect substrate specificity or enzyme dimerization. Mutation appears to result in haploinsufficiency of C2GnT activity. C2GnT-I haploinsufficiency is sufficient for loss of core 2 O-glycan expression and galectin-1 resistance
additional information
T60A
-
about 65% of the wild-type in vitro activity, mutation results in a significant increase in electrophoretic mobilities of the protein